ATAI Life Sciences BV (ATAI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ATAI Life Sciences BV (ATAI) has a cash flow conversion efficiency ratio of -0.106x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.09 Million) by net assets ($198.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ATAI net asset quality index to measure how much of total assets are equity-financed.
ATAI Life Sciences BV - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how ATAI Life Sciences BV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ATAI Life Sciences BV (ATAI) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
ATAI Life Sciences BV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ATAI Life Sciences BV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xinjiang Tecon Animal Husbandry Bio-Technology Co Ltd
SHE:002100
|
0.087x |
|
Heineken Bhd
KLSE:3255
|
0.423x |
|
Capital Southwest Corporation
NASDAQ:CSWC
|
-0.058x |
|
Zhejiang Shaoxing RuiFeng Rural Commercial Bank Co Ltd
SHG:601528
|
-0.086x |
|
Kinco Automation (Shanghai) Co. Ltd. A
SHG:688160
|
N/A |
|
Telecom Argentina SA ADR
NYSE:TEO
|
0.093x |
|
Alimak Hek Group AB
ST:ALIG
|
0.115x |
|
Rusta AB (publ)
ST:RUSTA
|
0.081x |
Annual Cash Flow Conversion Efficiency for ATAI Life Sciences BV (2019–2025)
The table below shows the annual cash flow conversion efficiency of ATAI Life Sciences BV from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see ATAI Life Sciences BV stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $222.00 Million | $-102.67 Million | -0.462x | +34.61% |
| 2024-12-31 | $116.55 Million | $-82.44 Million | -0.707x | -105.43% |
| 2023-12-31 | $244.32 Million | $-84.12 Million | -0.344x | +12.41% |
| 2022-12-31 | $265.77 Million | $-104.47 Million | -0.393x | -139.88% |
| 2021-12-31 | $385.96 Million | $-63.25 Million | -0.164x | +24.74% |
| 2020-12-31 | $95.37 Million | $-20.77 Million | -0.218x | -65.90% |
| 2019-12-31 | $59.78 Million | $-7.85 Million | -0.131x | -- |
About ATAI Life Sciences BV
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder… Read more